New HPV vaccine trial aims to protect kids and teens from cancer

NCT ID NCT07377656

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: International Vaccine Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a bivalent HPV vaccine in healthy infants (9 months), toddlers (15 months), children (2-5 years), and unmarried young women (15-20 years) in Ghana. Researchers want to see if the vaccine is safe and triggers a strong immune response, especially when given alongside routine childhood vaccines. The trial is still recruiting and will compare vaccinated groups to a placebo group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bivalent human papillomavirus (HPV) vaccine
What this could lead to: If successful, this could help protect young children and women against HPV-related cancers, potentially simplifying vaccination schedules.
What could go wrong: This is an early phase 2 proof-of-concept study with only 115 participants, so results may not apply broadly. Safety and immune response are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV VACCINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papilloma virus infection cervical cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HPV VACCINE

Contacts and locations

Locations

Dodowa Health Research Center
RECRUITING

Accra, Ghana

More trials for these conditions

Other studies related to the condition(s) this trial covers.